Subcision (subcutaneous incisionless surgery) is the standard surgical technique for releasing fibrotic, tethered acne scars that pull the surface of the skin downward. When superficial textural treatments—such as fractional lasers, chemical peels, and microneedling—fail to elevate depressed acne scars, the underlying failure is anatomical: surface energy cannot dissolve dense, vertical bands of type I and type III collagen anchoring the reticular dermis to the deep subcutaneous fascia.
However, the clinical execution of subcision has evolved substantially since its initial description by Orentreich and Orentreich in 1995:
- Instrument mechanics. The traditional sharp triangular Nokor needle (18-gauge or 20-gauge) has largely been replaced in modern dermatologic practice by long blunt-tip cannulas (18G to 22G, 70 mm). Sharp cutting blades carry high rates of hematoma formation, prolonged ecchymosis, dermal gouging, and accidental facial nerve or vessel laceration. Blunt cannulas dissect tissue planes via shear radial force, cutting complication rates while requiring only one or two lateral entry points per cheek.
- The biological re-tethering failure mode. When performed as standalone monotherapy, between 30% and 50% of severed rolling scars re-anchor during the normal 3-to-6-week wound contraction cascade. Without a physical interposition spacer—such as hyaluronic acid (HA), autologous platelet-rich fibrin (PRF), poly-L-lactic acid (Sculptra), or polymethylmethacrylate (Bellafill)—myofibroblasts re-approximate the severed tissue planes.
- FDA clearance context. While most dermal fillers and autologous biologics are deployed off-label as subcision spacers under clinician discretion, Bellafill (Suneva Medical) holds formal US FDA Premarket Approval (PMA P020012/S009, approved December 2014) specifically indicated for the correction of moderate-to-severe atrophic, distensible facial acne scars on the cheek in patients over the age of 21.
- Skin of color safety. Subcision operates entirely in the deep dermal and subdermal planes (1.5 to 2.5 mm beneath the skin surface). By completely bypassing epidermal basal melanocytes, subcision maintains a post-inflammatory hyperpigmentation (PIH) rate below 5% in Fitzpatrick phototypes IV–VI, compared to a 20% to 40% PIH incidence frequently observed with high-fluence ablative fractional CO2 lasers.
The following guide details the clinical triage of acne scar morphology, instrument physics, biological spacer mechanisms, complication prevention, recovery timelines, and realistic pricing.
Which types of acne scars actually respond to subcision?
Subcision is not a universal treatment for every indented acne mark. Attempting to subcise untethered or sharp-walled scars leads to surgical failure and unnecessary tissue trauma. Dermatologic scar revision classifies atrophic acne scars into three distinct morphological categories based on the Jacob classification system (Jacob et al., JAAD 2001):
| Scar Morphology | Anatomical Characteristics | Subcision Candidacy | Primary Indicated Modality |
|---|---|---|---|
| Rolling Scars (4 mm to >5 mm wide) | Broad, shallow depressions with gentle sloping edges; bound down to subcutaneous tissue by dense vertical and diagonal fibrous tracts | Primary Indication (Gold Standard) | Blunt cannula subcision + immediate filler/biologic spacer |
| Boxcar Scars (1.5 mm to 4.0 mm wide) | Sharp, punched-out vertical margins with a flat, fibrotic base; may be superficial (0.1–0.5 mm) or deep (>0.5 mm); superficial forms lack deep fascial anchors | Secondary / Selective (effective only for deep, bound-down variants; ineffective for shallow dermal boxcars) | Fractional ablative laser, punch elevation, or fully ablative Erbium:YAG |
| Ice-Pick Scars (<2 mm diameter) | Deep, narrow, epithelialized tracts extending vertically into the deep reticular dermis or subcutis; V-shaped cross-section | Contraindicated (0% Efficacy) | Focal high-strength TCA CROSS chemical reconstruction or 1.5–2.0 mm punch excision |
SCAR CROSS-SECTION ANATOMY & SUBSICION VECTOR
Rolling Scar (Subcision Target) Ice-Pick Scar (Contraindicated)
___ ___ ___ ___
/ \ / \ | \ / |
/ \ / \ | \ / |
| Epidermis / Dermis | | Epidermis | \ / |
=====\=====================/=========|==============|======V======|==== (Dermal-SubQ Boundary)
\ Dense Fibrous / | | Narrow Epithelial
\ Tether Bands / | | Tract (Needs TCA CROSS)
--------\---------------/------------|--------------|-----------------
\ / |
====> [ Blunt Cannula Plane ] ===> |
-------------------------------------|--------------------------------
Subcutaneous Fat | Subcutaneous Fat
The Manual "Stretch Test"
Clinicians determine whether an atrophic scar is surgically bound down using the manual stretch test. The provider places two fingers on either side of the depression and applies lateral traction:
- Distensible / Bound Scars: If the scar partially or completely smooths out under lateral skin tension, the dermal base is mobile but tethered at its base; it is an ideal candidate for subcision and filler augmentation.
- Fixed / Fibrotic Non-Distensible Scars: If the scar remains deeply depressed and rigid under tension, or exhibits sharp vertical walls with dense dermal sclerosis, superficial subcision alone will not elevate the floor; it requires focal chemical reconstruction (TCA CROSS), punch elevation, or surgical excision.
Blunt cannula vs Nokor needle: why tool choice determines bruising and hematoma risk
Historically, subcision was performed exclusively with sharp-edged surgical needles, most notably the Nokor needle (a 1.5-inch needle with a small, triangular lancet blade at its tip) or standard 18G to 20G hypodermic beveled needles. While sharp needles slice through fibrous bands with minimal manual resistance, their sharp edges cut everything indiscriminately—including dermal blood vessels, sensory nerve filaments, and superficial fat lobules.
In a landmark randomized split-face comparative trial published by Gheisari et al. (Journal of Cosmetic Dermatology, 2019), patients underwent subcision with an 18G Nokor needle on one facial side and an 18G/21G blunt cannula on the contralateral side:
| Parameter | Sharp Nokor Needle (18G–20G) | Blunt-Tip Subcision Cannula (18G–22G, 70 mm) | Clinical Significance |
|---|---|---|---|
| Dissection Mechanism | Sharp planar cutting with triangular blade | Mechanical blunt dissection and shear release | Cannula pushes vessels and nerves aside rather than severing them |
| Hematoma Formation Rate | 15% to 20% of treated areas | 0% in comparative trials | Nokor blades frequently lacerate the transverse facial artery or subdermal venous plexus |
| Ecchymosis (Bruising) Duration | 7 to 14 days (often severe, tracking downward into neck) | 3 to 5 days (mild, localized) | Significantly lower patient social downtime with blunt cannulas |
| Number of Skin Entry Points | 20 to 50+ punctures (each scar requires individual needle entry) | 1 to 2 lateral puncture sites per cheek (made with a 18G pilot needle) | Dramatically reduces procedural PIH, surface scabbing, and infection entry portals |
| Risk of Surface Gouging / Dermal Dents | High (if the sharp blade tilts superficially, it cuts the papillary dermis) | Negligible (blunt tip cannot accidentally incise the overlying dermis) | Prevents secondary surgical scar formation and textural irregularities |
| Tactile "Strumming" Feedback | Low resistance (blade cuts effortlessly without distinct acoustic feedback) | High resistance (distinct "pop" or strumming sensation as fibrous bands snap) | Confirms complete anatomical release of tethered bands across the entire field |
ENTRY PORTAL COMPARISON
NOKOR NEEDLE SUBSICION BLUNT CANNULA FIELD SUBSICION
(Multiple Punctures Across Face) (Single Lateral Pilot Entry Point)
[X] [X] [X] [X] [Pilot Entry (18G)]
\ \ \ \ \
[X] [X] [X] [X] ====> [Fan Dissection]
\ \ \ \ / / \
[X] [X] [X] [X] * * *
(20-50 Bleeding Entry Wounds) (Single access covers entire cheek)
Modern subcision technique utilizes a 70 mm, 18G or 21G blunt cannula introduced through a single pre-auricular or mandibular angle pilot hole created with an 18G sharp needle. Tumescent local anesthesia (lidocaine with epinephrine and sodium bicarbonate buffer) is infiltrated across the subdermal plane. The cannula is then advanced horizontally in a fanning pattern across the entire scarred aesthetic unit.
The surgeon uses a combination of horizontal piston movements and vertical lifting sweeps. As the blunt tip encounters dense vertical scar bands, the clinician feels and hears a distinct snapping or strumming sensation as the fibrous septae are physically torn from the fascia without transecting major vascular networks.
Why do subcised scars re-tether without a filler spacer or biostimulator?
A frequent frustration encountered in standalone subcision monotherapy is early visual improvement followed by partial or complete scar relapse 3 to 6 weeks later. Patients report that their scars appeared 70% elevated immediately following the procedure, but gradually sank back to their pre-treatment depth within a month.
This phenomenon is governed by the biology of wound healing:
- Immediate False Elevation (Edema & Hematoma): The initial elevation observed during days 1 through 5 is largely driven by tumescent fluid retention, localized inflammatory edema, and micro-hematoma pooling beneath the severed dermis.
- The Proliferative Phase (Days 3 to 21): Once the fibrous bands are severed, a dead space is created between the reticular dermis and the subcutaneous fat. As part of normal tissue repair, platelets degranulate, laying down an acute fibrin-fibronectin provisional matrix.
- Myofibroblast Differentiation & Wound Contraction (Weeks 2 to 6): Platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-β1) stimulate local fibroblasts to differentiate into α-smooth muscle actin-expressing myofibroblasts. These contractile cells grip the newly synthesized collagen fibers and generate mechanical tension, physically pulling the overlying dermis back down toward the deep fascia.
- Re-Tethering Rate: In published surgical series (Nilforoushzadeh et al., J Cosmet Dermatol 2019; Alam et al., Dermatol Surg 2005), 30% to 50% of rolling acne scars re-attach in the absence of an interposition barrier.
To prevent this biological contracture, modern dermatologic protocols place a physical spacer into the dissected subdermal plane immediately following mechanical release. The spacer physically separates the roof of the scar from the underlying floor, preventing myofibroblast cross-linking while providing an extracellular scaffold for de novo neocollagenesis.
Which fillers and biologics are used post-subcision (Bellafill, HA, Sculptra, PRF)?
Injecting an immediate spacer converts subcision from a temporary mechanical disruption into a permanent structural tissue reconstruction. Clinicians utilize four primary classes of spacer biomaterials, each with distinct longevity profiles, collagen-stimulating mechanics, and regulatory clearances.
SPACER COMPARISON MATRIX: MECHANISM, LONGEVITY & REGULATORY STATUS
Material Primary Mechanism Longevity FDA Status for Acne Scars
─────────────────────────────────────────────────────────────────────────────────────────────
Bellafill (PMMA) Permanent PMMA microsphere 5+ Years FDA PMA Approved (P020012)
collagen matrix (Permanent) Specific Cheek Indication
─────────────────────────────────────────────────────────────────────────────────────────────
Hyaluronic Acid Immediate hydrophilic physical 6–18 Months Off-label for acne scars
(e.g., Voluma/Restylane) space holder (Standard dermal filler)
─────────────────────────────────────────────────────────────────────────────────────────────
Sculptra (PLLA) Subdermal biostimulation & 2+ Years Off-label for acne scars
fibroblast activation (Approved for facial folds)
─────────────────────────────────────────────────────────────────────────────────────────────
Autologous PRF/PRP Fibrin scaffold + 14-day Biological scaffold Regulated as autologous
continuous growth factors (3–6 mo remodeling) clinical procedure (510k kits)
─────────────────────────────────────────────────────────────────────────────────────────────
1. Bellafill (PMMA Microspheres + Bovine Collagen)
Bellafill (Suneva Medical) is uniquely positioned as the only dermal filler holding an explicit FDA Premarket Approval (PMA P020012/S009) for distensible atrophic facial acne scars on the cheek.
- Composition: 20% non-resorbable polymethylmethacrylate (PMMA) precision microspheres (30–50 µm diameter) suspended in 80% purified bovine collagen gel with 0.3% lidocaine.
- Pivotal Trial Evidence: In the double-blind, randomized, sham-controlled multicenter pivotal registration trial (N=147), 64% of Bellafill-treated acne scar patients achieved clinical success (defined as at least a 2-point improvement on the 4-point Acne Scar Rating Scale, ASRS) at 6 months, compared to 33% in the control group. Long-term follow-up demonstrated that correction was maintained at 12 months with a favorable safety profile.
- Mechanism as a Spacer: The bovine collagen carrier provides immediate physical spacing during the critical 4-week wound-healing window. Over the subsequent 1 to 3 months, macrophages resorb the bovine collagen, while the non-immunogenic PMMA microspheres stimulate endogenous fibroblast encapsulation, laying down permanent autologous type I collagen.
- Clinical Caveat: Because Bellafill contains bovine collagen, patients must undergo a mandatory intradermal skin test 4 weeks prior to treatment to screen for bovine collagen allergy. Furthermore, Bellafill is non-reversible; misplaced superficial injection can create permanent visible nodules. It must only be injected in the immediate subdermal plane beneath fully released scars by experienced surgeons.
For a comprehensive analysis of PMMA chemistry and long-term retention data, see Bellafill permanent PMMA filler profile.
2. Hyaluronic Acid (HA) Gels
Hyaluronic acid dermal fillers (such as Restylane Lyft, Juvéderm Voluma, or Belotero Balance) are widely utilized as temporary, reversible spacers.
- Mechanism: HA provides high viscoelastic lift (G') that physically prevents the severed dermis from collapsing back onto the fascial bed.
- Longevity: 6 to 18 months, depending on the cross-linking density and enzymatic degradation rate.
- Reversibility Advantage: Unlike biostimulators, HA can be rapidly dissolved with intralesional hyaluronidase if overcorrection, superficial Tyndall effect (bluish discoloration), or a vascular compromise occurs.
- Dosing Caution: Low-volume micro-aliquots (0.02 to 0.05 mL per scar base) must be deposited strictly in the subdermal plane. Superficial dermal pooling of high-G' HA creates visible, firm nodules.
For technical parameters on HA viscoelastic properties, see Juvéderm vs Restylane family guide.
3. Poly-L-Lactic Acid (Sculptra / PLLA)
Hyperdilute Sculptra (PLLA microparticles reconstituted with 8 to 10 mL of sterile water and lidocaine) acts as a global biostimulatory spacer.
- Mechanism: PLLA microparticles elicit a sub-inflammatory foreign-body response, recruiting CD68+ macrophages and fibroblasts that deposit de novo type I and type III collagen over 3 to 6 months.
- Best Use Case: Patients with extensive fields of confluent rolling scars across the lateral cheeks and temples accompanied by mid-face volumetric lipoatrophy.
- Technique: Injected via blunt cannula in a retrograde cross-hatching fan immediately after field subcision.
4. Autologous Platelet-Rich Fibrin (PRF) and PRP
Autologous blood concentrates represent an entirely natural, non-foreign-body spacer modality.
- Mechanism: Liquid injectable PRF (i-PRF) forms an uncrosslinked 3D fibrin polymer scaffold inside the subcised pocket. As detailed in comparative kinetic literature (Miron et al., Clin Oral Investig 2017), PRF continuously releases physiological concentrations of PDGF, VEGF, TGF-β1, and epidermal growth factor (EGF) over 10 to 14 days.
- Trial Evidence: Controlled clinical trials (e.g., Nilforoushzadeh et al., J Cosmet Dermatol 2021; ClinicalTrials.gov NCT02482324) demonstrate that combining subcision with autologous PRF/PRP accelerates re-epithelialization, reduces post-procedural purpura duration by 40%, and provides sustained volumetric elevation without any risk of granuloma or vascular occlusion.
For a direct comparison of autologous concentrate mechanics, see PRP vs PRF biological differences.
Is subcision safer than laser resurfacing for darker skin (Fitzpatrick IV–VI)?
Post-inflammatory hyperpigmentation (PIH) is the single greatest risk in aesthetic scar revision for patients of African, South Asian, East Asian, and Hispanic descent. When energy-based devices (such as fully ablative or high-density fractional CO2 lasers) deliver thermal energy across the dermo-epidermal junction, basal melanocytes become hyperactivated, resulting in severe, long-lasting hypermelanosis in 20% to 40% of cases.
ANATOMICAL DEPTH & PIH RISK PROFILES
Surface Layer Laser Resurfacing Zone Subcision Surgical Plane
───────────────────────────────────────────────────────────────────────────────────────────
Epidermis (Melanocytes) ======> [ HIGH THERMAL INJURY ] =======> [ Completely Spared ]
(Direct Melanocyte Trigger) (No Surface Disruption)
───────────────────────────────────────────────────────────────────────────────────────────
Papillary / Reticular Dermis => [ Thermal Micro-Zones ] =======> [ Spared Dermal Matrix ]
───────────────────────────────────────────────────────────────────────────────────────────
Subcutaneous Fat & Fascia ====> [ Minimal Energy Reached ] ====> [ MECHANICAL RELEASE ]
(Target Fibrotic Bands)
───────────────────────────────────────────────────────────────────────────────────────────
PIH Risk (Fitzpatrick IV–VI) : 20% to 40%+ < 5% (with Blunt Cannula)
Subcision is uniquely safe in skin of color because of its strict anatomical depth:
- Melanocyte Sparing: The subcision cannula operates at a depth of 1.5 to 2.5 mm within the subcutaneous fat and deep reticular dermis. It does not generate heat and causes zero disruption to the overlying epidermal basal layer where melanocytes reside.
- Clinical PIH Incidence: Published clinical series in darker skin phototypes consistently document a PIH rate below 5% when subcision is performed with blunt cannulas. Any transient pigmentation that does occur is typically restricted to the 1–2 lateral needle entry points, which can be protected with post-procedure silicone sheeting and topical hydroquinone or cysteamine.
- Primary Modality Choice: For moderate-to-severe rolling scars in Fitzpatrick IV–VI skin, subcision with a filler spacer is frequently the primary and final foundational treatment, eliminating the need for aggressive ablative lasers.
For comprehensive safety protocols in ethnic skin, see acne scar treatments in skin of color and PIH prevention in aesthetic procedures.
What are the common complications: hematoma, nodules, and persistent swelling?
While blunt cannula subcision has dramatically improved the safety profile of scar surgery, complications can arise if proper surgical planes are breached.
COMPLICATION PROFILE & CLINICAL MANAGEMENT
Complication Etiology Prevention Management Protocol
────────────────────────────────────────────────────────────────────────────────────────────────────
Subcutaneous Laceration of facial vessels Tumescent anesthesia with Immediate compression (10 min);
Hematoma (sharp needles >> cannulas) epinephrine; blunt cannulas warm compresses; needle aspiration
(18G–21G) if fluctuant after 7–10 days
────────────────────────────────────────────────────────────────────────────────────────────────────
Superficial Dermal Spacer deposited too Inject strictly in subdermal Hyaluronidase for HA; intralesional
Nodules superficially or unevenly plane; avoid high-volume bolus 5-FU/triamcinolone for PLLA/PMMA
────────────────────────────────────────────────────────────────────────────────────────────────────
Facial Nerve Cannula passes too deep near Maintain superficial Spontaneous resolution within
Neuropraxia marginal mandibular nerve subcutaneous plane above SMAS 3–6 weeks; clinical monitoring
────────────────────────────────────────────────────────────────────────────────────────────────────
Infection / Biofilm Bacterial contamination of Aseptic prep; single lateral Oral cephalexin or doxycycline;
entry portal entry point; sterile drape drainage if purulent
────────────────────────────────────────────────────────────────────────────────────────────────────
1. Hematoma Formation
- Pathophysiology: Accumulation of blood within the dissected subcutaneous cavity, most commonly resulting from sharp Nokor needle laceration of subdermal venous branches or branches of the facial artery.
- Prevention: Infiltration of epinephrine-containing tumescent anesthesia 15 minutes prior to subcision to induce robust vasoconstriction; mandatory use of blunt-tip cannulas.
- Management: Firm manual compression applied for 10 continuous minutes immediately upon withdrawal of the instrument. If an expanding hematoma develops post-operatively, it should be monitored closely; organized fluctuant hematomas that do not resorb within 7 to 10 days can be gently aspirated using an 18G needle under sterile conditions to prevent secondary fibrotic nodule formation.
2. Dermal Nodules and Foreign-Body Granulomas
- Pathophysiology: Placement of spacer materials (HA, Sculptra, or Bellafill) within the intradermal rather than subdermal layer, or localized clumping of biostimulatory microparticles.
- Management: For hyaluronic acid nodules, prompt intralesional infiltration of 15 to 30 IU of hyaluronidase dissolves the collection within 24 to 48 hours. For non-resorbable PMMA (Bellafill) or PLLA (Sculptra) nodules, intralesional micro-droplet injections of 5-fluorouracil (50 mg/mL) mixed with low-dose triamcinolone acetonide (2.5 to 5.0 mg/mL) can flatten the inflammatory tissue without causing local skin atrophy.
3. Transient Neuropraxia
- Pathophysiology: Temporary blunt traction or tumescent compression of sensory nerve branches (infraorbital, zygomaticofacial, or mental nerves) or motor branches (marginal mandibular branch of the facial nerve).
- Presentation: Transient numbness, tingling, or temporary asymmetric lower lip depression.
- Prognosis: Blunt cannula traction injuries almost universally resolve spontaneously within 2 to 6 weeks as axonal conduction recovers. True nerve transection is exceedingly rare with blunt cannulas.
How much does acne scar subcision cost, and what is the recovery timeline?
Recovery Timeline
| Post-Procedure Timepoint | Expected Clinical Presentation | Recommended Patient Activities |
|---|---|---|
| Hours 0 to 24 | Significant facial fullness from tumescent fluid; mild pinpoint bleeding at entry sites; minimal pain | Apply cold compresses (15 min on/off); sleep with head elevated 30 degrees |
| Days 2 to 4 | Maximum localized edema; development of yellowish-purple bruising along lower cheeks and jawline | Resume gentle cleansing; apply mineral sunscreen; avoid vigorous cardiovascular exercise |
| Days 5 to 7 | Edema resolves by 70–80%; bruising fades; pilot entry scabs slough off cleanly | Social downtime ends; makeup can be applied over entry points; resume light exercise |
| Weeks 2 to 4 | Residual micro-swelling resolves; initial collagen remodeling phase begins; true scar elevation emerges | Evaluation for touch-up or secondary modalities (TCA CROSS, microneedling) |
| Months 3 to 6 | Mature neocollagenesis stabilizes; final structural elevation achieved (permanent if PMMA or well-spaced) | Long-term photographic assessment |
Pricing and Session Planning
Acne scar subcision is a specialized surgical procedure billed on a cash-pay basis. Costs vary based on the geographic market, provider credentials (board-certified dermatologist vs plastic surgeon), the total surface area treated, and the choice of concurrent filler spacer:
- Standalone Blunt Cannula Subcision: $500 to $1,500 per session (covers full cheeks and temples under tumescent local anesthesia).
- Subcision Combined with Hyaluronic Acid (HA) Filler: $1,200 to $2,400 per session (includes surgical release plus 1 to 2 syringes of cross-linked HA spacer).
- Subcision Combined with Autologous PRF / PRP: $1,000 to $1,800 per session (includes blood draw, centrifugation processing, and subdermal liquid PRF graft).
- Subcision Combined with Bellafill (FDA-Approved PMMA): $1,800 to $3,500 per session (reflects surgical release plus high-longevity PMMA syringes; requires prior skin testing).
Most patients with moderate-to-severe rolling acne scarring require 2 to 4 sessions spaced 6 to 8 weeks apart to achieve 50% to 80% global scar elevation.
Frequently asked questions
Is subcision good for acne scars?
Subcision is considered the gold-standard surgical technique specifically for rolling atrophic acne scars that are bound down to subcutaneous tissue. It is ineffective as monotherapy for narrow ice-pick scars (which require focal TCA CROSS) or shallow boxcar scars (which require fractional lasers or RF microneedling).
How much does subcision cost for acne scar removal?
Standalone subcision typically costs $500 to $1,500 per session. When combined with immediate filler spacers (such as hyaluronic acid, autologous PRF, Sculptra, or Bellafill), pricing ranges from $1,200 to $3,500 per session, depending on the volume and type of material injected.
How long do subcision results last?
The mechanical release of fibrous scar tethers is permanent. When an immediate spacer prevents scar re-attachment during the initial 6-week healing cascade, the elevated tissue bed remains stable. Permanent fillers like Bellafill maintain correction for 5+ years, while temporary HA fillers resorb after 9 to 18 months, leaving behind 40% to 60% permanent correction from newly generated endogenous collagen.
Is microneedling or subcision better for acne scars?
They address completely different anatomical layers. Microneedling and RF microneedling induce dermal collagen remodeling to improve surface roughness and shallow textural irregularities (depths up to 1.5–3.5 mm). Subcision operates beneath the dermis to sever dense fascial tethers. For rolling scars, subcision must be performed first to release the tether; microneedling alone cannot pull an anchored scar upward.
Can subcision make acne scars worse?
When performed properly with a blunt cannula, worsening of scars is rare. However, if sharp Nokor needles are angled too superficially, they can inadvertently cut the reticular dermis, resulting in surface gouging or new textural depressions. Similarly, injecting excessive filler superficially can cause visible dermal nodules or the Tyndall effect.
Do I need filler with subcision?
While not strictly mandatory, dermatologic studies show that 30% to 50% of severed rolling scars re-tether due to natural myofibroblast wound contraction if no spacer is placed. Injecting an immediate physical spacer (HA, PRF, Sculptra, or Bellafill) maintains tissue plane separation, preventing scar relapse and maximizing permanent elevation.
Sources
- Jacob CI, Dover JS, Kaminer MS. Acne scarring: A classification system and review of treatment options. J Am Acad Dermatol. 2001;45(1):109-117. Available at: https://pubmed.ncbi.nlm.nih.gov/11423843/
- Gheisari M, Iranmanesh B, Saghi B. Blunt cannula subcision is more effective than Nokor needle subcision for acne scars treatment. J Cosmet Dermatol. 2019;18(1):172-178. Available at: https://pubmed.ncbi.nlm.nih.gov/29524284/
- Nilforoushzadeh MA, et al. Comparison of two methods of subcision Nokor and blunt blade in acne scars treatment. J Cosmet Dermatol. 2019;18(6):1788-1793. Available at: https://pubmed.ncbi.nlm.nih.gov/31131976/
- Orentreich DS, Orentreich N. Subcutaneous incisionless (subcision) surgery for the correction of depressed scars and wrinkles. Dermatol Surg. 1995;21(6):543-549. Available at: https://pubmed.ncbi.nlm.nih.gov/7773602/
- FDA CDRH PMA Database: P020012/S009 Bellafill (ArteFill) Premarket Approval for Atrophic Distensible Facial Acne Scars on the Cheek (Decision Date: December 2014). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P020012S009
- ClinicalTrials.gov: Subcision Combined With Autologous Platelet-Rich Plasma in Atrophic Acne Scars (NCT02482324). Available at: https://clinicaltrials.gov/study/NCT02482324
- Alam M, et al. Subcision for acne scarring: technique and outcomes in 40 patients. Dermatol Surg. 2005;31(3):310-317. Available at: https://pubmed.ncbi.nlm.nih.gov/15841633/
- Kobayashi E, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig. 2016;20(9):2353-2360. Available at: https://pubmed.ncbi.nlm.nih.gov/26809431/
